Daiichi Sankyo dismantles nearly 4.7 billion yen of mature drugs, accelerating the transformation into the field of oncology

According to Nihon Keizai Shimbun, on the 26th local time, Daiichi Sankyo announced at the board meeting that it had passed a resolution to release 11 mature drugs including the antihypertensive drug "Acecol" and the antibacterial drug "Banan" in Japan.

As of March 31, 2020, the sales price of these 11 drugs was 4.

In fact, as early as July 2018, Daiichi Sankyo had sold the manufacturing and marketing rights of 41 mature drugs in Japan to Alfresa Pharmaceuticals.

In this regard, Daiichi Sankyo said that due to the emergence of generic drugs, the profitability of generic drugs has been lower than that of new drugs.

The company plans to develop 7 new molecular entities from 2018 to 2025.

In addition, at almost the same time, Daiichi Sankyo also recruited Ken Takeshita from Gilead’s cell therapy business unit and appointed him as the head of Daiichi Sankyo’s global R&D department and the interim head of clinical research.